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Sunmary Urinary ql excretion is independent of the main indices of tumour activity in myelomatosis (serum
paraprotein, serum ,B2-microglobulin, serum creatinine and urinary light chain production). The mean (±s.d.)
at presentation was 40.7+22.6nmol .,umol ucr 1, compared to 25.4+4.8nmol . gmolucr- in controls.
Urinary levels at presentation are significantly related to prognosis, the higher the level the poorer the
prognosis. However, when these levels have been stratified according to the corresponding level of serum /B2m,
the level adds little as a prognostic factor.
Several biochemical indices have been found to be
valuable as guides to prognosis in myelomatosis,
they include serum creatinine, paraprotein urinary
free light chain excretion and haemoglobin levels
(Durie & Salmon, 1975). More recently the serum
f2-microglobulin level has been confirmed to be a
powerful prognostic indicator (Child et al., 1983;
Bataille et al., 1984, Cuzick et al., 1985).
Nevertheless, the variation of the course of the
disease within the subsets defined by combinations
of these indicators warrants further study to try to
improve our predictions at the individual patient
level.
There is growing evidence that the increased
urinary excretion of modified nucleosides is a
common feature of many types of advanced cancers
(Borek et al., 1983) including lymphomas (Salvatore
et al., 1983; Rasmunson et al., 1983). The modified
nucleosides are produced by post-transcriptional
enzymatic action; tRNA contains the highest and
most varied number of modified nucleosides. No
retrieval pathway exists for these compounds,
ensuring that they are not randomly inserted into
the macromolecules (Borek, 1983; Dirheimer, 1983).
The catabolites of tRNA are excreted into the urine
without reabsorption and consist of pseudouridine
(i/) and possibly as many as 50 methylated
nucleosides. Pseudouridine is generally excreted in
concentrations of 10 to 100 times that of other
modified nucleosides both in healthy subjects and
cancer patients. There are previous reports
indicating that l excretion levels tends to carry as
much information in terms of its relation to tumour
mass and activity as a formal analysis of the
spectrum of modified nucleosides (Rasmunson et al.,
1983); but others favour the simultaneous analysis
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of several nucleosides (Borek et al., 1983; Heldman
et al., 1983).
In this paper we report the levels of urninary /
excretion in myelomatosis, determine its role as a
prognostic indicator alone, and investigate whether
it can add information once the patients have been
stratified for serum f2m levels.
Materials and methods
Patients
The 264 patients were all entered into the Medical
Research Council Vth myelomatosis trial and aged
less than 75 years old. The control group consisted
of 31 healthy individuals aged between 20 and 60
years.
The urinary nucleosides were first isolated by
affinity chromatography on boronate Affi-gel 667
obtained from Bioard (Watford, UK), as described
by Gehrke et al. (1978). Pseudouridine was then
assayed by reverse phase chromatography (Kuo et
al., 1978) on a 300 x 5mm Spherisorb 5 ODS
column in conjunction with an Applied Chromato-
graphy Systems HPLC apparatus, and the absor-
bance monitored at 254nm, 0.1 AUFS, 20M1 of
reconstituted nucleosides (equiv. to lOpl of urine)
was injected on to the column. The i peak was
isocraticly eluted by 10mM ammonium phosphate
buffer, pH5.1, containing 5% methanol, during the
first 4min of the chromatogram. The flow rate was
1 mlmin-1 at a pressure of 2000psi. The rest of the
nucleosides were then batch eluted by raising the
methanol content to 50% in one step, and after
3min the column was re-equilibrated for the next
run. The peak heights were measured and compared
to a range of u/ standards. The q/ concentration in
urine is given as nmol.umol urinary creatinine-
(ucr).
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The serum ,B2m was assayed by radial immuno-
diffusion using antisera obtained from Dako,
(Copenhagen, Denmark), the myeloma serum
paraproteins and urinary free light chain were
assayed in the Department of Immunology,
University of Birmingham as previously described
(Medical Research Council, 1984), and the urinary
creatinine determined by the Jaffe reaction.
Survival curves were drawn for subgroups of
patients defined by their f2m or i levels using the
method of Kaplan and Meier (1958). The statistical
significance ofdifferences in the survival distribution
between the sub-groups was tested using the log-
rank test (Peto et al., 1977) before and after
covariate adjustment.
Results
The / assay including the isolation step was highly
reproducible, it gave a mean recovery of 96+6%
of a 0.307nmol1-' solution in 20 replicate
measurements.
The mean (+s.d.) level of urinary / of 25.5
+4.8nmol.iimol ucr- ' in the controls is comparable
to other published results (Salvatore et al., 1983;
Rasmunson et al., 1983; Borek et al., 1983). There
was no evidence for a correlation between the q/
excretion and the age or surface area in the control
group.
A survey of the urinary / levels in myeloma
patients at presentation showed that the mean
(±s.d.) of 40.7+22.6nmol.pmolucr'- is highly
significantly increased compared to that of the
controls Z=9.26 (P<0.001).
A correlation matrix was computed to examine
the correlation coefficients of urinary t excretion
levels with the main biochemical indices of tumour
activity in myelomatosis. The correlation
coefficients are as follows: each pair of analytes and
their correlation coefficients were: urinary il versus
serum paraprotein, r=0.116; urinary t/ versus
urinary light chain, r=0.04; urinary i versus serum
creatinine, r=0.13 and urinary ,l, versus serum #2-
microglobulin, r=0.25 (P<0.01).
This showed that urinary il was independent of
paraprotein production light chain excretion and
serum creatinine, but weakly correlated to serum
,B2m levels at presentation. There were no
significant differences of the ql excretion levels in
myeloma of IgA, IgG or light chain only type.
Prognostic significance ofurinary q/ excretion
Based on an examination of the distribution of
urinary ql levels at presentation the patients
were divided into 3 groups of comparable size.
Group 1 <30nmol. imol ucr '. Group 2
30-40mol.,mol ucr-1 and Group 3
>40nmol.,umol ucr-. The survival according to
this stratification is shown in Figure 1. There is a
highly significant linear trend for prognosis to
become worse with a rising level of urinary t, Chi
square for trend (1 df)=9.85; P=0.0017. The
corresponding survival curves for the patients
stratified according to their serum /32m levels at
presentation are shown in Figure 2. The strong
prognostic effect of this parameter is apparent, the
Co .0
0 ._
Time (d)
Figure 1 Survival probability of patients with
myelomatosis stratified according to urinary i
concentration (nmol.ymol ucr-1) at presentation.
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Figure 2 Survival probability of patients with
myelomatosis stratified according to serum ,B2m level
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Chi square for trend, 31.15, is highly significant
(P= <0.00001). It will be seen that the majority of
early deaths occurred in patients with a serum
32m>8mgl-'.
The statistical significance of the presentation
level of urinary on survival after stratification for
serum fl2m level is shown in Table I. It can be seen
that after serum fl2m levels are taken into account
urinary level is no longer a significant prognostic
factor. Conversely after adjusting the prognostic
significance for the level of urinary level the Chi
square for trend remains at 22.5 (P=0.00001).
Discussion
An increased urinary excretion of modified
nucleosides, including tl occurs in a wide spectrum
of cancers, see Borek (1983) for a comprehensive
review. Haematological neoplasms including acute
leukaemias in children (Heldman et al., 1983b) and
adults (Heldman et al., 1983a; Nielsen & Killman,
1983) as well as chronic granulocytic leukaemia
(Nielsen & Killman et al., 1983; Heldman et al.,
1983c) have been reported as showing rises in
urinary modified nucleoside excretion. By
comparison with the present results, and restricting
the comparison to those reports using similar
HPLC assay techniques, it appears that the levels
of excretion in myelomatosis can often excede
those in other neoplasms (on average double the
control level for the last samples from patients who
died due to tumour progression). For example, the
average urinary excretion of 8 adult patients with
acute leukaemia was reported as 107pmol 24h-'
compared to 73pmol 24h-1 for 25 healthy controls
(47% above control level) (Heldman et al., 1983a).
There are reports of age dependent changes in
modified nucleoside excretion including (Tritsch
et al., 1979). In children the levels decrease linearly
with age from birth to 16 years old (Heldman et al.,
1983b). Conversely the mean levels of excretion
were reported as 12.9nmol .pmol ucr- creatinine at
age 25 and 38.4nmol. pmol ucr- at age 90 rising by
5.9nmol.pmol cr-1 per decade (Tritsch et al., 1979).
However, this was based on observations on only
21 patients with very few individuals included in the
age range 40-75 y. The majority of patients in the
present study are in this age bracket. In contrast
our control group of 31 healthy individuals aged
20-60y did not show any correlation between age
and excretion.
The present study has drawn attention to the
independence of the excretion in myelomatosis from
the levels of serum paraprotein, immunoglobulin
type, and urinary free light chain excretion. The serum
fl2m and urinary levels are only weakly
correlated. Considered alone the level of urinary
Table I Effect of presentation serum ,B2-microglobulin on the significance of
urinary / level as a prognostic factor in myelomatosis.
fl2-microglobulin I Obs. x2
mg 1- nmol.pmolucr1 No deaths OIE trend P
<4 <30 14 1 0.89 0.01 0.9435
>30 15 2 1.50
>40 6 0 0.0
>4 <30 24 3 0.59 0.84 0.3585
>30 28 7 1.14
>40 19 6 1.26
>6 <30 12 4 0.82 1.14 0.2851
>30 19 6 0.74
>40 18 9 1.51
>8 <30 9 4 0.91 0.13 0.7174
>30 20 8 0.88
>40 28 16 1.10
>12 <30 5 3 0.86 0.89 0.3461
>30 18 9 0.75
>40 29 19 1.23
Adjusted for fl2m <30 64 15 0.79 3.0 0.0833
>30 100 32 0.87
>40 100 50 1.21
Non-adjusted <30 64 15 0.62 9.85 0.0017
for ,B2m >30 100 32 0.84
>40 100 50 1.44866 S.H. S0RESEN et al.
at presentation is of prognostic significance, but
adds little prognostic information to that contained
in the serum fl2m level. This study once again
reinforcing the opinion that serum f2m level an
extremely powerful prognostic factor in myeloma-
tosis. (Cuzick et al., 1985).
Thomale and Nass (1983) have suggested that
modified nucleoside excretion in cancer results from
a combination of intrinsic alterations in enzymatic
activity and secondary events resulting from the
overall metabolism of the host as the tumour
grows. The results of the present study could be
explained by a similar hypothesis. Preliminary
studies of the spectrum of methylated nucleosides
excreted in myelomatosis indicate that a high level
of q excretion is associated with an increased
excretion of several methylated nucleosides, and is
not an isolated event (S0rensen, unpublished data).
In this context it is of interest that indicators of
protein synthetic activity of the tumour (serum
paraprotein levelandurinarylightchainexcretion) are
not correlated with urinary & excretion. This
favours the concept that the urinary i is a
reflection of the tumour mass and the probable
increase of divergence of tRNA metabolism away
from normal with increasing cytogenetic aberration
within the tumour cell line.
S.H. S0rensen and E.H. Cooper are supported by the
Yorkshire Cancer Research Campaign. K.A. Kelly is
supported by the Cancer Research Campaign. D.A. Brown
is supported by MRC Grant Number G8216939. We are
grateful to Miss Jill Siddall for her assistance with the
statistical analyses, and to Miss C. Evans for secretarial
assistance.
References
BATAILLE, R., CORENIER, J. & SANY, J. (1984). Beta-2-
microglobulin in myeloma: Optimal use for staging,
prognosis and treatment - A prospective study of 160
patients. Blood, 63, 468.
BOREK, E., SHARMA, O.K. & WAALKES, T.P. (1983). New
applications of urinary nucleoside markers. Recent
Results Cancer Res., 84, 301.
BOREK, E. (1983). Transfer RNA and its by-products as
human markers. In Cancer Markers, Sell, S. (ed) p.
445. Humana Press: Clifton, NJ.
CHILD, J.A., CRAWFORD, S.H., NORFOLK, D.R.,
O'QUIGLEY, J., SCARFFE, J.H. & STRUTHERS, L.P.L.
(1983). Evaluation of serum P2-microglobulin as a
prognostic indicator in myelomatosis. Br. J. Cancer,
47, 111.
CUZICK, J., COOPER, E.H. & MACLENNAN, I.C.M. (1985).
The prognostic value of serum 12-microglobulin
compared with other presentation features in
myelomatosis. Br. J. Cancer, 52, 1.
DIRHEIMER, G. (1983). Chemical nature, properties,
location and physiological and pathological variations
of modified nucleosides. Recent Results Cancer Res.,
84, 15.
DURIE, B.G.H. & SALMON, S.E. (1975). A clinical staging
system for multiple myeloma. Cancer, 36, 842.
GEHRKE, C.W., KUO, K.C., DAVIS, G.E., SUITS, R.D.,
WAALKES, T.P. & BOREK, E. (1978). Quantitative high
performance liquid chromatography of nucleosides in
biological materials. J. Chromatography, 150, 455.
HELDMAN, D.A., GREVER, M.R. & TREWYN, R.W.
(1983a). Differential excretion of modified nucleosides
in adult acute leukemia. Blood, 61, 291.
HELDMAN, D.A., GREVER, M.R., MISER, J.S. & TREWYN,
R.W. (1983b). Relationship of urinary excretion of
modified nucleosides to disease status in childhood
lymphoblastic leukemia. J. Natl Cancer Inst., 71, 269.
HELDMAN, D.A., GREVER, H.R., SPREICHER, C.E. &
TREWYN, R.W. (1983c). Urinary excretion of modified
nucleosides in chronic myelogenous leukemia. J. Lab.
Clin. Med., 101, 783.
KAPLAN, E.L. & MEIER, P. (1958). Noparmetric
estimation from incomplete observation. J. Am.
Statist. Assoc., 53, 457.
KUO, K.C., GEHRKE, C.W. & McCURIE, R.A. (1978).
Rapid quantitative high performance liquid column
chromatography of pseudouridine. J. Chromatography,
145, 383.
MEDICAL RESEARCH COUNCIL WORKING PARTY ON
LEUKAEMIA IN ADULTS. (1984). Analysis and
management of renal failure in the IVth myelomatosis
trial. Brit. Med. J., 288, 1411.
NIELSEN, H.R. & KILLMANN, S.A. (1983). Urinary
excretion of y-aminoisobutyrate and pseudouridine in
acute and chronic myeloid leukemia. J. Natl Cancer
Inst., 71, 887.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others. (1977).
Design and analysis of randomized clinical trial
requiring prolonged observation of each patient ii
Analysis and examples. Br. J. Cancer, 35, 1.
RASMUNSON, J.T., BJORK, G.R., DAMBER, L. & 6 others.
(1983). Evaluation of carcinoembryonic antigen, tissue
polypeptide antigen, placental alkaline phosphatase
and modified nucleosides as biological markers in
malignant lymphomas. Recent Results Cancer Res., 84,
331.
SALVATORE, F., COLONNA, A., COSTANZO, F., RUSSO,
T., ESPOSITO, F. & CIMINO, F. (1983). Modified
nucleosides in body fluids of tumor-bearing patients.
Recent Results Cancer Res., 184, 360.
THOMALE, J. & NASS, G. (1983). Increasing urinary levels
of modified nucleosides and bases during tumor
development in mice. Recent Results Cancer Res., 184,
378.
TRITSCH, G.L., LUCH, J.H., EVANS, J.T. & HITTELMAN,
A. (1979). Age dependence of human urinary
pseudouridine excretion. Biochem. Med., 22, 387.